| Protocol | Title |
|---|---|
| E1697 | Phase III Randomized Study of Four Weeks High Dose IFN-A2B in Stage
T2B NO, T3A-B NO, T4A-B NO, and T1-4, N1A, 2A (microscopic) Melanoma
Activation Date: 22-dec-1998 |
| E2602 | A Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with
Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor.
Activation Date: 05-sep-2003 ECOG Participants(requires Adobe Acrobat) |
| E2607 | A Phase II Trial of Dasatinib in Patients with Unresectable Locally
Advanced or Stage IV Mucosal, Acral and Solar Melanomas
Activation Date: 01-may-2009 ECOG Participants(requires Adobe Acrobat) |
| S0438 | A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772)
with Either CCI-779 (Temsirolimus; NSC-683864) or R115777
(Tipifarnib; NSC-702818) in Metastatic Melanoma
Activation Date: 11-jun-2008 Suspended: 15-feb-2009 |
All contents copyright © 1998 Eastern Cooperative Oncology Group.
All rights reserved.
Revised: 07/03/09